Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer

被引：0

作者：

Haratani, Koji ^{[1
]}

Nakamura, Atsushi ^{[2
]}

Mamesaya, Nobuaki ^{[3
]}

Sawa, Kenji ^{[4
]}

Shiraishi, Yoshimasa ^{[5
]}

Saito, Ryota ^{[6
]}

Tanizaki, Junko ^{[7
]}

Tamura, Yosuke ^{[8
]}

Hata, Akito ^{[9
]}

Tsuruno, Kosuke ^{[10
]}

Sakamoto, Tomohiro ^{[11
]}

Teraoka, Shunsuke ^{[12
]}

Oki, Masahide ^{[13
]}

Watanabe, Hiroshi ^{[14
]}

Tokito, Takaaki ^{[15
]}

Nagata, Kenji ^{[16
]}

Masuda, Takeshi ^{[17
]}

Nakamura, Yasushi ^{[18
]}

Sakai, Kazuko ^{[19
]}

Chiba, Yasutaka ^{[20
]}

Ito, Akihiko ^{[18
]}

Nishio, Kazuto ^{[19
]}

Yamamoto, Nobuyuki ^{[12
]}

Nakagawa, Kazuhiko ^{[1
]}

Hayashi, Hidetoshi ^{[1
]}

机构：

[1] Kindai Univ, Fac Med, Dept Med Oncol, Osakasayama, Osaka, Japan

[2] Sendai Kousei Hosp, Dept Pulm Med, Sendai, Miyagi, Japan

[3] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan

[4] Osaka Metropolitan Univ, Grad Sch Med, Dept Resp Med, Osaka, Japan

[5] Kyushu Univ, Grad Sch Med Sci, Dept Resp Med, Fukuoka, Fukuoka, Japan

[6] Tohoku Univ, Sch Med, Dept Resp Med, Sendai, Miyagi, Japan

[7] Kishiwada City Hosp, Div Med Oncol, Kishiwada, Osaka, Japan

[8] Osaka Med & Pharmaceut Univ Hosp, Resp Med & Thorac Oncol, Takatsuki, Osaka, Japan

[9] Kobe Minimally Invas Canc Ctr, Div Thorac Oncol, Kobe, Hyogo, Japan

[10] Iizuka Hosp, Dept Resp Med, Iizuka, Fukuoka, Japan

[11] Tottori Univ, Fac Med, Dept Multidisciplinary Internal Med, Div Resp Med & Rheumatol, Yonago, Tottori, Japan

[12] Wakayama Med Univ, Internal Med 3, Wakayama, Japan

[13] Natl Hosp Org Nagoya Med Ctr, Dept Resp Med, Nagoya, Aichi, Japan

[14] Saka Gen Hosp, Dept Resp Med, Shiogama, Miyagi, Japan

[15] Kurume Univ, Sch Med, Dept Internal Med, Div Respirol Neurol & Rheumatol, Kurume, Fukuoka, Japan

[16] Itami City Hosp, Dept Resp Med, Itami, Hyogo, Japan

[17] Hiroshima Univ Hosp, Dept Resp Med, Hiroshima, Hiroshima, Japan

[18] Kindai Univ, Fac Med, Dept Pathol, Osakasayama, Osaka, Japan

[19] Kindai Univ, Fac Med, Dept Genome Biol, Osakasayama, Osaka, Japan

[20] Kindai Univ Hosp, Clin Res Ctr, Osakasayama, Osaka, Japan

来源：

BRITISH JOURNAL OF CANCER | 2024年 / 130卷 / 11期

关键词：

NIVOLUMAB EFFICACY;

D O I：

10.1038/s41416-024-02662-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundImmune-related adverse events (irAEs) have been found to predict PD-L1 inhibitor efficacy in metastatic NSCLC. However, the relation of irAEs to clinical outcome for nonmetastatic NSCLC has remained unknown.MethodsIn this multicenter prospective study of Stage III NSCLC treated with PACIFIC regimen, the relation of irAEs to PFS was evaluated by 8-week landmark analysis to minimise lead-time bias as well as by multivariable analysis adjusted for baseline factors. irAEs were categorised as mild or nonmild according to whether they were treated with systemic steroid.ResultsMedian PFS was 16.0 months, not reached, and 9.7 months for patients without (85 cases) or with mild (21 cases) or nonmild (21 cases) irAEs, respectively. Multivariable analysis indicated that nonmild irAEs were associated with poor PFS, with HRs of 3.86 (95% CI, 1.31-11.38) compared with no irAEs and 11.58 (95% CI, 2.11-63.63) compared with mild irAEs. This pattern was consistent after irAE grade, the number of durvalumab doses and immune profiles (PD-L1 score, CD8+ tumour-infiltrating lymphocyte density, and tumour mutation burden) were taken into consideration.ConclusionsThe development of mild irAEs might predict a better survival outcome, whereas immunosuppressive steroid-treated irAEs were associated with a worse outcome, regardless of baseline clinical and immune profiles.

引用

页码：1783 / 1794

页数：12